Real-world Evidence Solutions Market Anticipates a Reach of US$ 5 billion by 2031, Propelled by an 14.4% CAGR | Growth Plus Reports

Pune, Feb. 20, 2024 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global Real-world Evidence Solutions Market is expected to clock US$ 5 billion by 2031 and to grow at a CAGR of 14.4% during the forecast period.

The global Real-World Evidence (RWE) Solutions Market is experiencing rapid growth, fueled by the increasing demand for robust evidence generation, advancements in data analytics technologies, and the growing emphasis on value-based healthcare delivery. Real-world evidence solutions enable stakeholders in the healthcare ecosystem to leverage real-world data (RWD) from diverse sources, including electronic health records (EHRs), claims data, registries, and wearable devices, to generate actionable insights, inform clinical research, and support evidence-based decision-making.

Get a Sample Copy of the Research Report:

Real-world Evidence Solutions Market Scope

Report Attribute Details
Market Size Value in 2022 US$ 1.7 billion
Revenue forecast in 2031 US$ 5 billion
CAGR 14.4%
Base Year for Estimation 2022
Forecast Period 2023-2031
Historical Year 2021
Segments Covered Component, Application, End-user, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Market Overview:
Real-world evidence encompasses data collected from routine clinical practice and healthcare delivery settings, reflecting the real-world patient experience, treatment patterns, and outcomes. Real-world evidence solutions facilitate the analysis, integration, and interpretation of RWD to generate meaningful insights into disease epidemiology, treatment effectiveness, safety profiles, and healthcare utilization patterns. By complementing traditional clinical trial data with real-world data, stakeholders can gain a comprehensive understanding of healthcare interventions’ real-world impact and optimize patient outcomes.

Key Market Drivers:

  1. Shift towards Value-Based Healthcare: Healthcare systems worldwide are transitioning from fee-for-service models to value-based care paradigms, emphasizing the delivery of high-quality, cost-effective care that improves patient outcomes and reduces healthcare expenditures. Real-world evidence solutions play a pivotal role in supporting value-based decision-making by providing insights into treatment effectiveness, patient adherence, and healthcare resource utilization in real-world settings.
  1. Advancements in Data Analytics Technologies: Technological innovations in data analytics, machine learning, and artificial intelligence have revolutionized the analysis and interpretation of real-world data. Advanced analytics platforms enable stakeholders to extract actionable insights from large and complex datasets, identify treatment patterns, predict disease outcomes, and tailor interventions to individual patient needs, driving the adoption of real-world evidence solutions across the healthcare ecosystem.
  1. Regulatory Support and Industry Initiatives: Regulatory agencies and industry organizations are increasingly recognizing the value of real-world evidence in supplementing traditional clinical trial data and informing healthcare decision-making. Regulatory guidelines, such as the U.S. FDA’s Framework for Real-World Evidence Program and the European Medicines Agency’s (EMA) EMA Roadmap to 2025, provide guidance on the use of real-world evidence in regulatory decision-making, fostering industry collaboration and innovation in real-world evidence solutions.

Competitive Landscape:
The Real-World Evidence Solutions Market is characterized by a diverse ecosystem of vendors, including technology providers, data analytics companies, contract research organizations (CROs), and healthcare IT firms. Key players focus on product innovation, data quality and interoperability, regulatory compliance, and strategic partnerships to gain a competitive edge. Collaboration with healthcare stakeholders, research consortia, and academic institutions fosters innovation and drives market growth.

Challenges and Opportunities:
Despite significant advancements, challenges such as data quality and standardization, patient privacy concerns, and regulatory complexities remain barriers to the widespread adoption of real-world evidence solutions. However, opportunities exist for stakeholders to address these challenges through data governance frameworks, interoperability standards, and patient engagement strategies. Emerging technologies, such as blockchain and federated learning, present additional opportunities for enhancing data security, transparency, and collaboration in real-world evidence generation.

Table of Content

    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
    1. Research Approach
    2. Data Collection Methodology
    3. Data Products
      1. Secondary Products 
      2. Primary Products 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
    1. Services
    2. Data Sets
      1. Claims Data
      2. Pharmacy Data
      3. Patient-Powered Data
      4. Clinical Settings Data
      5. Registry-Based Data Sets
    1. Drug Development and Approvals
      1. Neurology
      2. Oncology
      3. Cardiovascular Disease
      4. Immunology
      5. Other Therapeutic Areas
      6. Medical Device Development And Approvals
    2. Post-Market Surveillance
    3. Market Access Reimbursement/Coverage Decision Making
    4. Clinical And Regulatory Decision-Making
    1. Pharmaceutical & Medical Device Companies
    2. Healthcare Providers
    3. Healthcare Payers
    4. Others

Browse full TOC here

Future Outlook:

The Real-World Evidence Solutions Market is poised for continued growth, driven by the increasing adoption of value-based care models, advancements in data analytics technologies, and the expanding role of real-world evidence in regulatory decision-making and healthcare policy. As stakeholders leverage real-world evidence to drive innovation, optimize healthcare delivery, and improve patient outcomes, the market will witness further innovation and collaboration, ushering in a new era of evidence-based healthcare.

In conclusion, real-world evidence solutions represent a transformative force in healthcare, enabling stakeholders to harness the power of real-world data to drive innovation, inform decision-making, and improve patient outcomes. By embracing technological advancements, fostering collaboration, and addressing regulatory and data challenges, stakeholders can unlock the full potential of real-world evidence and drive positive change in healthcare delivery and patient care.


  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
  • Comprehensive quantitative and qualitative insights at segment and sub-segment level
  • Covid 19 impact trends and perspective
  • Granular insights at global/regional/country level
  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
  • Blanket coverage on competitive landscape
  • Winning imperatives
  • Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market


  • Distributor Landscape Assessment
  • Pricing Intelligence
  • Customer Base Assessment
  • Investment & Initiatives Analysis
  • ‘Business Profile’ of Key Players

Buy this Premium Research Report:

Browse other reports:

According to the deep-dive market assessment study by Growth Plus Reports, the global medical clothing market was valued at US$ 90.3 billion in 2021 and is expected to register a revenue CAGR of 7.6% to reach US$ 174.58 billion by 2030.

According to the deep-dive market assessment study by Growth Plus Reports, the global immunohematology market was valued at US$ 1.01 billion in 2021 and is expected to register a revenue CAGR of 3.90% to reach US$ 1.41 billion by 2030.

According to the deep-dive market assessment study by Growth Plus Reports, the global kidney stone management market was valued at US$ 1.70 billion in 2021 and is expected to register a revenue CAGR of 5.4% to reach US$ 2.76 billion by 2030.

According to the deep-dive market assessment study by Growth Plus Reports, the global mass spectrometry market was valued at US$ 15.20 billion in 2021 and is expected to register a revenue CAGR of 7.80% to reach US$ 32.23 billion by 2030.

According to the deep-dive market assessment study by Growth Plus Reports, the global metastatic breast cancer market was valued at US$ 17 billion in 2021 and is expected to register a revenue CAGR of 9.8% to reach US$ 39.43 billion by 2030.

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.

CONTACT: Manan Sethi Director, Market Insights Email: Phone no: +1 888 550 5009 Web:  Follow Us: LinkedIn | Twitter

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy